ArticleMethods in molecular biology (Clifton, N.J.)2025
Nuclear Morphology-Based Assessment of Cell Fates Induced by a Microtubule Targeting Agent as a Single Treatment or Combined with an Oncolytic Virus.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunofluorescence microscopy allows for the quantitative assessment of cell fate at single-cell resolution. This is required to analyze heterogeneous cell populations, as the assessment of average values of given parameters does not faithfully describe distinct states of specific subpopulations. As a case in point, we describe a methodology for characterizing the effects of a microtubule targeting agent, 2-methoxestradiol (2ME2), on T24 human bladder cancer cells. We employ an immunofluorescence-based assessment of nuclear morphology, DNA content, and the intracellular distribution pattern of microtubules for the identification/classification of cells undergoing mitosis or mitotic slippage. When combined with imaging-based identification of cells expressing a nonstructural oncolytic virus protein, this approach enables the assessment of the potential for combined treatment with a microtubule targeting agent and an oncolytic virus (e.g., the Epizootic Hemorrhagic Disease Virus-Tel Aviv University, EHDV-TAU).
Indexed as
Identifiers
40266520What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.